Comparative Pharmacology
Head-to-head clinical analysis: KEPPRA versus POTIGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEPPRA versus POTIGA.
KEPPRA vs POTIGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levetiracetam binds to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. It also inhibits high-voltage N-type calcium channels and reduces GABAergic and glycinergic inhibition.
Selective neuronal potassium channel opener; activates Kv7 channels (KCNQ) to stabilize neuronal membranes and reduce excitability.
500 mg orally twice daily, titrated up to 1500 mg twice daily as tolerated.
100 mg orally once daily for 1 week, then increase by 50-100 mg/day at weekly intervals to 300-400 mg/day in 2 divided doses; maximum 400 mg/day.
None Documented
None Documented
6-8 hours in adults; prolonged to 10-18 hours in renal impairment (CrCl <30 mL/min); clinical context: dosing interval adjustment required in renal disease.
Terminal elimination half-life is approximately 13-16 hours in healthy individuals, allowing twice-daily dosing. In patients with hepatic impairment, half-life may be prolonged (up to 30 hours).
Renal: 66% unchanged; 27% as inactive metabolite; 0.3% fecal.
Renal excretion accounts for approximately 25-30% of the administered dose as unchanged drug; the remainder is eliminated as metabolites via the biliary/fecal route (up to 70%) and further metabolized. Total recovery in urine and feces is >90%, with fecal excretion being the major route.
Category C
Category C
Antiepileptic
Antiepileptic